Medical Expertise

Pediatrics
Pediatric Infectious Diseases
Opportunistic Infections
Atypical Mycobacterial Infections
HIV infection
Immunodeficiencies
International Pediatric HIV Infection

Hospital Affiliation

University Hospital, Newark

INSURANCE PARTICIPATION

Insurance Participation: with Provider Number (where applicable)
The information below is subject to change and should not be relied upon until after it is verified with the insurance company. In addition, psychiatric providers should be contacted directly for information on their participation with managed care and insurance companies.

Aetna, Inc.

AmeriGroup

AmeriHealth of NJ

America's Choice Provider Network (ACPN)

Clover Health Plans

Devon Health Services/ULLICO

Horizon BCBS Managed Care

Horizon NJ Health

Horizon NJ Total Care(HNJH)

Horizon PPO Network

Medicaid

Medicare

MultiPlan

Prime Health Services, Inc.

Qual Care HMO

Qual Care PPO

Three Rivers Provider Network

UHC Comm/Oxford

United Healthcare Community Plan (formerly AmeriChoice of NJ, Inc.)

WellCare Health Plans

Languages

French
Spanish

Overview

I have been at New Jersey Medical School/Rutgers (formerly University of Medicine and Dentistry of
New Jersey) since 1992, first as a fellow in the well-known Oleske group and then as a faculty
member in the Department of Pediatrics (1994-ongoing). Since then, Pediatric HIV infection/AIDS has
been my professional focus and passion. Currently, my clinical activities encompass not only the
University Hospital but also Newark Beth Israel Medical Center and Cooperman-Saint Barnabas
Medical Center.

My early encounter with HIV/AIDS in children, a devastating and fatal condition, made me realize
the urgent need for further studies to answer many perplexing questions, acquire novel medical
knowledge, develop diagnostic methods, and discover new therapies. Consequently, I have
participated in over 70 cohort studies to better understand the disease process and improve the
outcomes of HIV infection in children. These investigations, which are still ongoing, involved
collaborations between many academic centers including UMDNJ/Rutgers. The outcomes of these
pioneering studies have been highly successful, enlightening and gratifying. I have witnessed and
participated in the development and implementation of Protocol 076, the master protocol that has
revolutionized the prevention of HIV transmission from mother to infant.

Throughout my medical career, I have collaborated with many universities all over the world to
develop treatment protocols through Pediatric AIDS Clinical Trials (PPACTG), IMPAACT. I served as
the Pediatric Director for the NJMS Clinical Trial Unit (CTU) and was responsible for the health
care team that provided care to a cohort of HIV-infected children and youth. I was also the
Principal Investigator at our site for Longitudinal Epidemiologic Study to Gain Insight into
HIV/AIDS in children and Youth (LEGACY), a multi-center CDC funded project. Since 2008, I have
been the Principal Investigator of the Pediatric HIV/AIDS Cohort Study (PHACS), a NIH
/NICHD funded grant through Harvard School of Public Health, which has 2 components, Surveillance
Monitoring of Antiretroviral Treatment and Toxicities (SMARTT), monitoring HIV exposed infants born
to HIV-infected mothers, and Adolescent Master Protocol (AMP), following perinatally infected
adolescents and young adults. Being a consistent contributor to the global effort for the development
of treatments to eradicate HIV/AIDS in children has been extremely

Education

M.D., 1982, State University School of Medicine, Haiti
B.S., 1974, Our Lady College of Cap-Haitien, Haiti

Licensure & Certification

Medical Licensure
New Jersey

Curriculum Vitae

View CV

Languages

French
Spanish

Areas Of Interest

"Opportunistic infections"

"Pediatric HIV infection"

" Atypical Mycobacterial Infection"

PHACS (AMP, SMARTT, AMP up)

PHACS(Pediatric HIV/AIDS Cohort Study)includes AMP (Adolescent Master Protocol), SMARTT(Surveillance Monitoring for Antiretroviral Toxicities Study) and AMP up.
SMARTT is a multi-center prospective cohort study, NIH/NICHD sponsored, whose major objective is to evaluate the short and long-term toxicities and consequences resulting from in utero and neonatal exposure of HIV non-infected infants to ART, including toxicities arising from mitochondrial dysfunction.
AMP Up:This is a prospective cohort study designed to define the impact of HIV infection and antiretroviral therapy (ART) on young adults with perinatal HIV infection as they transition into adulthood. A group of perinatally HIV-exposed, -uninfected (PHEU) young adults previously or currently enrolled in the PHACS AMP or SMARTT studies from a similar sociodemographic background and age distribution will be enrolled for comparison. Clinic visits at Entry, Year 3, and Year 6 with interval online data collection and chart abstraction.. Clinic visits will include clinical assessments (height, weight, and other body measurements, blood pressure and male circumcision status), neurocognitive functioning, mental health assessments, language and hearing assessments, real-time laboratory testing, and collection of specimens for central testing and for the PHACS Repository. Online data collection and chart abstraction will include interval medical diagnoses, ART, social history, reproductive health, height, weight, blood pressure, results of laboratory testing conducted for clinical care, and adherence, sexual behavior, quality of life, mental health and substance use. Testing for sexually transmitted infections (STI) will be done annually in real-time at the local testing laboratory if results are not available from current chart abstraction. In addition, urine from males and vaginal swab (preferred) or urine from females will be collected annually for research STI testing. HIV testing will be offered to PHEU participants at the Year 3 visit.
AMP:This is a prospective cohort study designed to define the impact of HIV
infection and antiretroviral therapy on pre-adolescents and adolescents
with perinatal HIV infection. A group of HIV-uninfected children with
perinatal exposure to HIV from a similar sociodemographic background
and age distribution are enrolled for comparison.
Domains to be investigated include growth and sexual maturation,
metabolic risk factors for cardiovascular disease, cardiac function, bone
health, neurologic, neurodevelopment, language, hearing and behavioral
function, and sexually transmitted infections (STI).
Population: HIV-infected and -uninfected children from 7 years of age (7th birthday)
up to but not including the 16th birthday born to HIV-infected mothers
Annual visits with medical, neurological, neurodevelopmental,
behavioral, language, growth, metabolic, mitochondrial, cardiac,
hearing, and laboratory studies